Fulcrum Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Fulcrum Asset Management's BMY Position: Q2 2026 in Review
Fulcrum Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 18% in Q2 2026, selling an estimated $121K and leaving 9,865 shares worth $578K. The position accounts for 0.06% of the portfolio, ranked #263.
Fulcrum Asset Management first reported a position in BMY in Q2 2025 and has held it in 5 quarters since. The position peaked at $716K in Q1 2026. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Fulcrum Asset Management held 9,865 shares of Bristol-Myers Squibb worth $578K as of Q2 2026.
- Fulcrum Asset Management sold 2,114 Bristol-Myers Squibb shares in Q2 2026, an estimated $121K.
- Bristol-Myers Squibb made up 0.06% of Fulcrum Asset Management's portfolio in Q2 2026, its #263 holding.
- Fulcrum Asset Management first reported a position in Bristol-Myers Squibb in Q2 2025 and has held it in 5 quarters since.
- Fulcrum Asset Management's Bristol-Myers Squibb position peaked at $716K in Q1 2026.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.